Read by QxMD icon Read


Yuming Jiang, Chuanli Chen, Jingjing Xie, Wei Wang, Xuefan Zha, Wenbing Lv, Hao Chen, Yanfeng Hu, Tuanjie Li, Jiang Yu, Zhiwei Zhou, Yikai Xu, Guoxin Li
To develop and validate a radiomics signature for the prediction of gastric cancer (GC) survival and chemotherapeutic benefits. In this multicenter retrospective analysis, we analyzed the radiomics features of portal venous-phase computed tomography in 1591 consecutive patients. A radiomics signature was generated by using the Lasso-Cox regression model in 228 patients and validated in internal and external validation cohorts. Radiomics nomograms integrating the radiomics signature were constructed, demonstrating the incremental value of the radiomics signature to the traditional staging system for individualized survival estimation...
September 14, 2018: EBioMedicine
Sainan An, Liwu Fu
There are several challenges towards the development and clinical use of small molecule inhibitors, which are currently the main type of targeted therapies towards intracellular proteins. PROteolysis-TArgeting Chimeras (PROTACs) exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. Recently, small-molecule PROTACs with high potency have been frequently reported. In this review, we summarize the emerging characteristics of small-molecule PROTACs, such as inducing a rapid, profound and sustained degradation, inducing a robust inhibition of downstream signals, displaying enhanced target selectivity, and overcoming resistance to small molecule inhibitors...
September 14, 2018: EBioMedicine
Gerardo Ferrer
No abstract text is available yet for this article.
September 12, 2018: EBioMedicine
Thomas Horvatits, Sven Pischke
No abstract text is available yet for this article.
September 10, 2018: EBioMedicine
Jing Zou, Xuping Xie, Huanle Luo, Chao Shan, Antonio E Muruato, Scott C Weaver, Tian Wang, Pei-Yong Shi
BACKGROUND: Vaccines are the most effective means to fight and eradicate infectious diseases. Live-attenuated vaccines (LAV) usually have the advantages of single dose, rapid onset of immunity, and durable protection. DNA vaccines have the advantages of chemical stability, ease of production, and no cold chain requirement. The ability to combine the strengths of LAV and DNA vaccines may transform future vaccine development by eliminating cold chain and cell culture with the potential for adventitious agents...
September 7, 2018: EBioMedicine
Yanning Liu, Guohua Lou, Aichun Li, Tianbao Zhang, Jinjin Qi, Dan Ye, Min Zheng, Zhi Chen
BACKGROUND: Mesenchymal stem cell (MSC)-derived exosome administration has been considered as a novel cell-free therapy for liver diseases through cell-cell communication. This study was aimed to determine the effects and mechanisms of AMSC-derived exosomes (AMSC-Exo) for acute liver failure (ALF) treatment. METHODS: AMSC-Exo were intravenously administrated into the mice immediately after lipopolysaccharide and D-galactosamine (LPS/GalN)-exposure and their effects were evaluated by liver histological and serum biochemical analysis...
September 6, 2018: EBioMedicine
Di Cheng, Junge Deng, Bin Zhang, Xiaoyu He, Zhe Meng, Guolin Li, Huilin Ye, Shangyou Zheng, Lusheng Wei, Xiaogeng Deng, Rufu Chen, Jiajia Zhou
BACKGROUND: MicroRNA-122 (miR-122), a pivotal liver-specific miRNA, is frequently repressed in hepatocellular carcinoma (HCC) and associated with poor prognosis. Long non-coding RNA (lncRNA) HOTAIR has been proved to function as an oncogene in multiple cancers including HCC. However, the relationship between HOTAIR and miR-122 in HCC remains largely unknown. METHODS: We investigated the function of HOTAIR and miR-122 in HCC cell models and a xenograft mouse model...
September 5, 2018: EBioMedicine
Yijin Wang, Shan Wang, Jian Wu, Yiyun Jiang, Haiying Zhang, Shujuan Li, Hongyang Liu, Changshuang Yang, Haijun Tang, Naizhou Guo, Maikel P Peppelenbosch, Lai Wei, Qiuwei Pan, Jingmin Zhao
Neurological manifestations are potentially associated with hepatitis E virus (HEV) infection in Europe, mainly attributed to genotype (GT) 3 HEV infection. In this study, we determined the frequency and causal relationship of HEV in patients with non-traumatic neurological disorders in China, where GT4 HEV is prevalent. 1117 consecutive patients diagnosed with neurological illnesses in a hospital of eastern China and 1475 healthy controls who took routine examination in the same hospital were tested for HEV by serology and molecular methods...
September 3, 2018: EBioMedicine
Yuan Li, Christoffer Soendergaard, Fredrik Holmberg Bergenheim, David M Aronoff, Ginger Milne, Lene Buhl Riis, Jakob Benedict Seidelin, Kim B Jensen, Ole Haagen Nielsen
BACKGROUND: Inhibition of tumor necrosis factor-α (TNF) signaling is beneficial in the management of ulcerative colitis (UC), but up to one-third of patients do not have a clinical response of relevance to TNF inhibitors during induction therapy (i.e. primary non-responders [PNRs]). Through production of prostaglandins (PGs) and thromboxanes, cyclooxygenase-2 (COX-2) affects inflammation and epithelial regeneration and may in this way be implicated in treatment resistance to TNF inhibitors...
September 3, 2018: EBioMedicine
Philip Supply
No abstract text is available yet for this article.
September 1, 2018: EBioMedicine
Jinyuan Xu, Aiai Shi, Zhilin Long, Liwen Xu, Gaoming Liao, Chunyu Deng, Min Yan, Aiming Xie, Tao Luo, Jian Huang, Yun Xiao, Xia Li
Characterizing functions of long noncoding RNAs (lncRNAs) remains a major challenge, mostly due to the lack of lncRNA-involved regulatory relationships. A wide array of genome-wide expression profiles generated by gene perturbation have been widely used to capture causal links between perturbed genes and response genes. Through annotating >600 gene perturbation profiles, over 354,000 causal relationships between perturbed genes and lncRNAs were identified. This large-scale resource of causal relations inspired us to develop a novel computational approach LnCAR for inferring lncRNAs' functions, which showed a higher accuracy than the co-expression based approach...
August 31, 2018: EBioMedicine
Dingxiao Zhang, Dean G Tang
No abstract text is available yet for this article.
August 31, 2018: EBioMedicine
Berthold Hocher, Carl-Friedrich Hocher
No abstract text is available yet for this article.
August 30, 2018: EBioMedicine
Ziyang Xu, Megan C Wise, Hyeree Choi, Alfredo Perales-Puchalt, Ami Patel, Edgar Tello-Ruiz, Jacqueline D Chu, Kar Muthumani, David B Weiner
BACKGROUND: Despite vigorous and ongoing efforts, active immunizations have yet to induce broadly neutralizing antibodies (bNAbs) against HIV-1. An alternative approach is to achieve prophylaxis with long-term expression of potent biologic HIV-1 inhibitors with Adeno-associated Virus (AAV), which could however be limited by hosts' humoral and cellular responses. An approach that facilitates in vivo production of these complex molecules independent of viral-vectored delivery will be a major advantage...
August 30, 2018: EBioMedicine
David E Spaner, Robertson Venema, Justin Huang, Peter Norris, Alan Lazarus, Guizhi Wang, Yonghong Shi
The intrinsic humoral immunodeficiency of chronic lymphocytic leukemia (CLL) is often managed with immunoglobulin replacement therapy (IgRT) to maintain IgG levels in the low-normal range (6-8 g/L) but optimal targets for IgG and timing to commence IgRT are unclear. IgG levels fell near 6 g/L at rates of -0.85±0.14 g/L/year in 51 patients who required treatment for CLL within 4.5±0.4 years from initial diagnosis and - 0.27±0.04 g/L/year in 40 patients with progressive disease who remained untreated after 8...
August 30, 2018: EBioMedicine
Mabel Toribio, Kathleen V Fitch, Lauren Stone, Markella V Zanni, Janet Lo, Chris de Filippi, Craig A Sponseller, Hang Lee, Ida Grundberg, Melanie A Thompson, Judith A Aberg, Steven K Grinspoon
BACKGROUND: People with HIV (PWH) demonstrate increased cardiovascular disease (CVD), due in part to increased immune activation, inflammation, and endothelial dysfunction. METHODS: In a randomized trial (INTREPID), 252 HIV-infected participants with dyslipidemia and no history of coronary artery disease were randomized (1:1) to pitavastatin 4 mg vs. pravastatin 40 mg for 52 weeks. Using a proteomic discovery approach, 92 proteins biomarkers were assessed using Proximity Extension Assay technology to determine the effects of statins on key atherosclerosis and CVD pathways among PWH...
August 30, 2018: EBioMedicine
Jing Ye, Zhen Wang, Ying Huang, Menglong Wang, Bin Que, Di Ye, Yao Xu, Yuan Wang, Tao Zeng, Yingzhong Lin, Jun Wan, Qingwei Ji
No abstract text is available yet for this article.
August 30, 2018: EBioMedicine
Jacek Budzyński
No abstract text is available yet for this article.
August 30, 2018: EBioMedicine
Hai Deng, Alena Shantsila, Pi Guo, Tatjana S Potpara, Xianzhang Zhan, Xianhong Fang, Hongtao Liao, Yang Liu, Wei Wei, Lu Fu, Shulin Wu, Yumei Xue, Gregory Y H Lip
BACKGROUND: Obesity or overweight is related to worse outcomes in patients with atrial fibrillation (AF) following catheter ablation (CA). The role of being underweight in relation to recurrent arrhythmias post AF ablation is less certain. We conducted a retrospective study to investigate the association of body mass index (BMI) with arrhythmia outcomes in AF patients undergoing CA. METHODS: In a cohort of 1410 AF patients (mean age 57.2 ± 11.6 years; 68% male) undergoing single CA, the association between BMI and AF ablation outcome was analyzed using BMI as a continuous variable and by four BMI categories (<18...
August 30, 2018: EBioMedicine
Zhihui Dong, Tianyue Pan, Yuan Fang, Zheng Wei, Shiyang Gu, Gang Fang, Yifan Liu, Yang Luo, Hao Liu, Tiejun Zhang, Meiyu Hu, Daqiao Guo, Xin Xu, Bin Chen, Junhao Jiang, Jue Yang, Zhenyu Shi, Ting Zhu, Yun Shi, Peng Liu, Weiguo Fu
BACKGROUND: Peripheral blood mononuclear cells (PBMNCs) and purified CD34+ cells (PCCs) are increasingly being used at treating no-option critical limb ischaemia (NO-CLI). We aimed to compare the efficacies and uncover the advantages associated with each treatment approach. METHODS: A randomised single-blinded non-inferiority trial (Number: NCT 02089828) was performed. NO-CLI patients were 1:1 randomised to the PBMNCs and PCCs groups, and compared in relation to safety and efficacy outcomes...
August 29, 2018: EBioMedicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"